Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 2/20 | 0.49 |
| ▸ | HRH1 | P35367 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | NMT1 | P30419 | 2/20 | 0.45 |
| ▸ | IKBKB | O14920 | 2/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29862550 | 0.98 | ROCK1 (0.48) | ROCK1HRH1HTR2CCHRM3SLC6A2 | |
| Hydrochloric Acid SCHEMBL5476262 | 0.98 | ROCK1 (0.48) | ROCK1HRH1HTR2CCHRM3SLC6A2 | |
| SCHEMBL5461406 | 0.91 | CHRNB2 (0.47) | ROCK1HTR2CSLC6A2IRAK4 | |
| Hydrochloric Acid SCHEMBL5454375 | 0.90 | CHRNB2 (0.46) | ROCK1SLC6A2HCRTR1HCRTR2IRAK4 | |
| SCHEMBL16764917 | 0.83 | ROCK1 (0.53) | ROCK1SLC6A2IKBKBCHUKIRAK4 | |
| SCHEMBL16764914 | 0.83 | ROCK1 (0.53) | ROCK1SLC6A2IKBKBCHUKIRAK4 | |
| SCHEMBL29586291 | 0.81 | HCRTR1 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL21047726 | 0.81 | HCRTR1 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL23707528 | 0.78 | HTR1A (0.39) | HTR2CHCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL23699137 | 0.77 | HTR1A (0.38) | HTR2CHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021404-A1 | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2007-01-25 | — | — | US | claimed |
| EP-1638939-A2 | AZA-RING DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2006-03-29 | — | — | EP | claimed |
| WO-2004113297-A9 | AZA-RING DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2005-11-24 | — | — | WO | claimed |
| WO-2004113297-A2 | AZA-RING DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2004-12-29 | — | — | WO | claimed |
| EP-3858813-A1 | QUINOLONE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITED ACTIVITY | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
| US-10723711-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10428034-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20180065943-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2018-03-08 | — | — | US | disclosed |
| US-9845301-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170029390-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2017-02-02 | — | — | US | disclosed |
| US-20070021404-A1 | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2007-01-25 | — | — | US | disclosed |
| EP-1638939-A2 | AZA-RING DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004113297-A9 | AZA-RING DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2005-11-24 | — | — | WO | disclosed |
| WO-2004113297-A2 | AZA-RING DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021404-A1 | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | ROCK1 1110/4885HRH1 667/4885HTR2C 60/4885 |
| US-20170029390-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | MAG, PYM1, HIF1AN | ROCK1 300/4885HRH1 1635/4885HTR2C 844/4885 |
| US-20180065943-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | MAG, PYM1, HIF1AN | ROCK1 300/4885HRH1 1635/4885HTR2C 844/4885 |
| US-10723711-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | MAG, PYM1, HIF1AN | ROCK1 300/4885HRH1 1635/4885HTR2C 844/4885 |
| US-10428034-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | MAG, PYM1, HIF1AN | ROCK1 300/4885HRH1 1635/4885HTR2C 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.